The Challenge Of Cmc Regulatory Compliance
Buster Krajcik
—
nnovation, including cell and gene therapies, biosimilars, and novel antibody formats, adds layers of complexity to CMC compliance. Emerging modalities often lack established regulatory precedents, forcing companies to engage in iterative